All patients
Age < 65y (younger) Age > 65y Asian type ECOG 0 ECOG 1 PD-L1 < 1% PD-L1 > 1% stage II stage III (locally advanced)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
es-BC - TNBC - NA - all population, immune chekpoint inhibitors vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMpassion-031 (all population), 2020 0.69 [0.25; 1.89]
0.69 [0.25 ; 1.89 ] IMpassion-031 (all population), 2020 1 0% 333 NA not evaluable deaths (OS) (extension)detailed results GeparNuevo, 2019 0.24 [0.03; 2.28]
0.24 [0.03 ; 2.28 ] GeparNuevo, 2019 1 0% 174 NA not evaluable events or deaths (EFS)detailed results IMpassion-031 (all population), 2020 0.76 [0.40; 1.44]
KEYNOTE-522, 2020 0.63 [0.43; 0.93]
0.66 [0.48 ; 0.92 ] IMpassion-031 (all population), 2020, KEYNOTE-522, 2020 2 0% 1,507 low not evaluable pCR detailed results GeparNuevo, 2019 1.45 [0.80; 2.63]
IMpassion-031 (all population), 2020 1.95 [1.26; 3.01]
KEYNOTE-522, 2020 13.60 [6.77; 27.33]
3.30 [0.99 ; 11.04 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020, KEYNOTE-522, 2020 3 93% 1,109 low not evaluable AE (any grade)detailed results IMpassion-031 (all population), 2020 0.49 [0.02; 14.69]
KEYNOTE-522, 2020 0.25 [0.01; 4.74]
0.33 [0.04 ; 3.09 ] IMpassion-031 (all population), 2020, KEYNOTE-522, 2020 2 0% 1,501 low not evaluable AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.10 [0.71; 1.72]
KEYNOTE-522, 2020 1.35 [1.01; 1.80]
1.27 [0.99 ; 1.62 ] IMpassion-031 (all population), 2020, KEYNOTE-522, 2020 2 0% 1,501 low not evaluable AE leading to death (grade 5)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
IMpassion-031 (all population), 2020 1.02 [0.06; 16.42]
0.97 [0.10 ; 9.43 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 0% 505 low not evaluable AE leading to treatment discontinuation (any grade)detailed results IMpassion-031 (all population), 2020 1.18 [0.70; 2.01]
1.18 [0.70 ; 2.01 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable SAE (any grade)detailed results GeparNuevo, 2019 0.88 [0.47; 1.66]
IMpassion-031 (all population), 2020 2.00 [1.20; 3.36]
1.36 [0.61 ; 3.02 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 74% 505 low not evaluable STRAE (any grade)detailed results IMpassion-031 (all population), 2020 1.58 [0.91; 2.75]
1.58 [0.91 ; 2.75 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable TRAE (any grade)detailed results IMpassion-031 (all population), 2020 0.98 [0.14; 7.05]
KEYNOTE-522, 2020 0.25 [0.03; 2.00]
0.51 [0.12 ; 2.15 ] IMpassion-031 (all population), 2020, KEYNOTE-522, 2020 2 0% 1,501 low not evaluable TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.15 [0.74; 1.77]
KEYNOTE-522, 2020 1.26 [0.96; 1.66]
1.23 [0.97 ; 1.55 ] IMpassion-031 (all population), 2020, KEYNOTE-522, 2020 2 0% 1,501 low not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-522, 2020 1.50 [0.16; 14.43]
1.50 [0.16 ; 14.43 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable TRAE leading to discontinuation (any grade)detailed results KEYNOTE-522, 2020 2.16 [1.53; 3.05]
2.16 [1.53 ; 3.05 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
KEYNOTE-522, 2020 10.08 [0.59; 173.00]
4.58 [0.46 ; 45.81 ] IMpassion-031 (all population), 2020, KEYNOTE-522, 2020 2 0% 1,501 low not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 0.87 [0.36; 2.09]
0.87 [0.36 ; 2.09 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.27 [0.91; 1.77]
1.27 [0.91 ; 1.77 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.40 [0.65; 3.02]
1.40 [0.65 ; 3.02 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Colitis TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 2.04 [0.07; 61.32]
KEYNOTE-522, 2020 3.51 [0.43; 28.62]
3.02 [0.51 ; 18.04 ] IMpassion-031 (all population), 2020, KEYNOTE-522, 2020 2 0% 1,501 low not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 0.50 [0.01; 25.13]
0.50 [0.01 ; 25.13 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 3.51 [0.43; 28.62]
3.51 [0.43 ; 28.62 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Diabetes TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
KEYNOTE-522, 2020 1.99 [0.09; 44.34]
1.54 [0.14 ; 17.56 ] IMpassion-031 (all population), 2020, KEYNOTE-522, 2020 2 0% 1,501 low not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.71 [0.63; 4.67]
1.71 [0.63 ; 4.67 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Dysgeusia TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 0.50 [0.01; 25.13]
0.50 [0.01 ; 25.13 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 2.29 [0.94; 5.58]
2.29 [0.94 ; 5.58 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.13 [0.82; 1.57]
1.13 [0.82 ; 1.57 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 0.51 [0.02; 15.24]
0.51 [0.02 ; 15.24 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
KEYNOTE-522, 2020 9.06 [0.52; 156.66]
4.26 [0.42 ; 42.77 ] IMpassion-031 (all population), 2020, KEYNOTE-522, 2020 2 0% 1,501 low not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
KEYNOTE-522, 2020 1.99 [0.09; 44.34]
1.54 [0.14 ; 17.56 ] IMpassion-031 (all population), 2020, KEYNOTE-522, 2020 2 0% 1,501 low not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 8.04 [0.46; 140.38]
8.04 [0.46 ; 140.38 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
KEYNOTE-522, 2020 3.00 [0.15; 59.96]
2.01 [0.19 ; 21.80 ] IMpassion-031 (all population), 2020, KEYNOTE-522, 2020 2 0% 1,501 low not evaluable Increase AST TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 9.67 [1.29; 72.54]
9.67 [1.29 ; 72.54 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 2.34 [1.13; 4.86]
2.34 [1.13 ; 4.86 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.06; 16.42]
KEYNOTE-522, 2020 2.53 [0.86; 7.45]
2.24 [0.82 ; 6.15 ] IMpassion-031 (all population), 2020, KEYNOTE-522, 2020 2 0% 1,501 low not evaluable Leucopenia TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 0.76 [0.57; 1.03]
0.76 [0.57 ; 1.03 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Myocarditis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.99 [0.09; 44.34]
1.99 [0.09 ; 44.34 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Myositis TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 2.04 [0.07; 61.32]
KEYNOTE-522, 2020 0.50 [0.01; 25.13]
1.11 [0.09 ; 14.55 ] IMpassion-031 (all population), 2020, KEYNOTE-522, 2020 2 0% 1,501 low not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 2.64 [1.01; 6.94]
2.64 [1.01 ; 6.94 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 7.03 [0.40; 124.15]
7.03 [0.40 ; 124.15 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.06 [0.82; 1.38]
1.06 [0.82 ; 1.38 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 4.00 [0.21; 75.85]
4.00 [0.21 ; 75.85 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.88 [0.62; 5.72]
1.88 [0.62 ; 5.72 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.20 [0.42; 3.43]
1.20 [0.42 ; 3.43 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 2.04 [0.07; 61.32]
KEYNOTE-522, 2020 1.50 [0.16; 14.43]
1.65 [0.25 ; 10.86 ] IMpassion-031 (all population), 2020, KEYNOTE-522, 2020 2 0% 1,501 low not evaluable Pyrexia TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 4.02 [0.50; 32.22]
4.02 [0.50 ; 32.22 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Rash TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.32; 3.23]
KEYNOTE-522, 2020 3.51 [0.43; 28.62]
1.37 [0.49 ; 3.84 ] IMpassion-031 (all population), 2020, KEYNOTE-522, 2020 2 2% 1,501 low not evaluable Sarcoidosis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 0.50 [0.01; 25.13]
0.50 [0.01 ; 25.13 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
KEYNOTE-522, 2020 15.50 [2.11; 114.09]
6.86 [0.60 ; 79.02 ] IMpassion-031 (all population), 2020, KEYNOTE-522, 2020 2 32% 1,501 low not evaluable Stomatitis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 11.10 [0.65; 189.37]
11.10 [0.65 ; 189.37 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.99 [0.09; 44.34]
1.99 [0.09 ; 44.34 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Uveitis TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 0.50 [0.01; 25.13]
0.50 [0.01 ; 25.13 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-522, 2020 1.51 [0.59; 3.82]
1.51 [0.59 ; 3.82 ] KEYNOTE-522, 2020 1 0% 1,170 NA not evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed results GeparNuevo, 2019 1.79 [0.06; 54.10]
1.79 [0.06 ; 54.10 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Abdominal pain AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
IMpassion-031 (all population), 2020 0.51 [0.02; 15.24]
0.65 [0.05 ; 8.46 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 0% 505 low not evaluable Alopecia AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
0.95 [0.06 ; 15.32 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 0% 505 low not evaluable Anaemia AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.12; 6.46]
IMpassion-031 (all population), 2020 1.21 [0.54; 2.69]
1.15 [0.55 ; 2.43 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 0% 505 low not evaluable Arthralgia AE (grade 3-4)detailed results GeparNuevo, 2019 1.80 [0.16; 20.23]
IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.54 [0.20 ; 12.07 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 0% 505 moderate not evaluable Asthenia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.54 [0.25; 9.32]
1.54 [0.25 ; 9.32 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Back pain AE (grade 3-4)detailed results GeparNuevo, 2019 0.44 [0.01; 13.37]
IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
0.63 [0.05 ; 8.30 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 0% 505 moderate not evaluable Blood creatinine increased AE (grade 3-4)detailed results GeparNuevo, 2019 0.05 [0.00; 0.89]
0.05 [0.00 ; 0.89 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Constipation AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.05; 14.46]
IMpassion-031 (all population), 2020 0.51 [0.02; 15.24]
0.71 [0.08 ; 6.14 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 0% 505 moderate not evaluable Cough AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
0.95 [0.06 ; 15.32 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 0% 505 low not evaluable Decreased appetite AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Diarrhoea AE (grade 3-4)detailed results GeparNuevo, 2019 5.49 [0.27; 111.35]
IMpassion-031 (all population), 2020 4.15 [0.46; 37.53]
4.58 [0.77 ; 27.06 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 0% 505 low not evaluable Dry skin AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
IMpassion-031 (all population), 2020 2.04 [0.07; 61.32]
1.43 [0.11 ; 18.75 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 0% 505 low not evaluable Dysgeusia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Dyspepsia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Dyspnoea AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
IMpassion-031 (all population), 2020 1.02 [0.14; 7.32]
0.99 [0.17 ; 5.78 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 0% 505 low not evaluable Epistaxis AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
0.95 [0.06 ; 15.32 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 0% 505 low not evaluable Fatigue AE (grade 3-4)detailed results GeparNuevo, 2019 0.47 [0.15; 1.45]
IMpassion-031 (all population), 2020 1.23 [0.37; 4.11]
0.74 [0.29 ; 1.92 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 24% 505 moderate not evaluable Febrile neutropenia AE (grade 3-4)detailed results GeparNuevo, 2019 1.82 [0.32; 10.20]
IMpassion-031 (all population), 2020 1.25 [0.61; 2.57]
1.32 [0.68 ; 2.57 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 0% 505 low not evaluable Headache AE (grade 3-4)detailed results GeparNuevo, 2019 1.79 [0.06; 54.10]
IMpassion-031 (all population), 2020 0.51 [0.02; 15.24]
0.95 [0.09 ; 10.58 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 0% 505 low not evaluable Hypertension AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 0.84 [0.35; 2.00]
0.84 [0.35 ; 2.00 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Hyperthyroidism AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
0.89 [0.02 ; 45.40 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Hypophysitis AE (grade 3-4)detailed results GeparNuevo, 2019 1.79 [0.06; 54.10]
1.79 [0.06 ; 54.10 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
0.89 [0.02 ; 45.40 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Increase AST AE (grade 3-4)detailed results GeparNuevo, 2019 5.49 [0.27; 111.35]
IMpassion-031 (all population), 2020 2.44 [0.62; 9.59]
2.80 [0.81 ; 9.75 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 0% 505 low not evaluable Increased ALT AE (grade 3-4)detailed results GeparNuevo, 2019 1.20 [0.26; 5.51]
IMpassion-031 (all population), 2020 0.91 [0.36; 2.30]
0.98 [0.44 ; 2.17 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 0% 505 low not evaluable Infusion-related reaction AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
IMpassion-031 (all population), 2020 1.02 [0.06; 16.42]
0.97 [0.10 ; 9.43 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 0% 505 low not evaluable Injury, poisoning and procedure AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.05; 14.46]
0.89 [0.05 ; 14.46 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Lacrimation increased AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Leucopenia AE (grade 3-4)detailed results GeparNuevo, 2019 0.84 [0.45; 1.57]
IMpassion-031 (all population), 2020 1.86 [0.76; 4.55]
1.17 [0.54 ; 2.51 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 51% 505 moderate not evaluable Mucosal inflammation AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 2.04 [0.07; 61.32]
2.04 [0.07 ; 61.32 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Myalgia AE (grade 3-4)detailed results GeparNuevo, 2019 1.82 [0.32; 10.20]
IMpassion-031 (all population), 2020 2.04 [0.07; 61.32]
1.86 [0.40 ; 8.67 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 0% 505 moderate not evaluable Nausea AE (grade 3-4)detailed results GeparNuevo, 2019 0.06 [0.00; 1.05]
IMpassion-031 (all population), 2020 0.28 [0.06; 1.38]
0.20 [0.05 ; 0.79 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 0% 505 low not evaluable Neutropenia AE (grade 3-4)detailed results GeparNuevo, 2019 0.83 [0.45; 1.52]
IMpassion-031 (all population), 2020 1.10 [0.65; 1.84]
0.98 [0.66 ; 1.45 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 0% 505 low not evaluable Oropharyngeal pain AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 2.04 [0.07; 61.32]
2.04 [0.07 ; 61.32 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Paraesthesia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.02 [0.02; 51.63]
1.02 [0.02 ; 51.63 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Peripheral neuropathy AE (grade 3-4)detailed results GeparNuevo, 2019 0.88 [0.33; 2.33]
IMpassion-031 (all population), 2020 0.40 [0.08; 2.09]
0.72 [0.31 ; 1.66 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 0% 505 moderate not evaluable Peripheral oedema AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 0.51 [0.02; 15.24]
0.51 [0.02 ; 15.24 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Peripheral sensory neuropathy AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 1.28 [0.34; 4.86]
1.28 [0.34 ; 4.86 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Pneumonitis AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.02; 45.40]
0.89 [0.02 ; 45.40 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Pruritus AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 0.25 [0.03; 2.26]
0.25 [0.03 ; 2.26 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Pyrexia AE (grade 3-4)detailed results IMpassion-031 (all population), 2020 4.11 [0.18; 91.86]
4.11 [0.18 ; 91.86 ] IMpassion-031 (all population), 2020 1 0% 331 NA not evaluable Rash AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.05; 14.46]
IMpassion-031 (all population), 2020 4.15 [0.46; 37.53]
2.30 [0.41 ; 12.93 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 0% 505 low not evaluable Stomatitis AE (grade 3-4)detailed results GeparNuevo, 2019 3.62 [0.16; 81.50]
IMpassion-031 (all population), 2020 6.20 [0.31; 124.85]
4.79 [0.55 ; 41.56 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 0% 505 low not evaluable Thrombocytopenia AE (grade 3-4)detailed results GeparNuevo, 2019 0.44 [0.04; 4.94]
0.44 [0.04 ; 4.94 ] GeparNuevo, 2019 1 0% 174 NA not evaluable Vomiting AE (grade 3-4)detailed results GeparNuevo, 2019 0.89 [0.05; 14.46]
IMpassion-031 (all population), 2020 2.05 [0.18; 22.82]
1.43 [0.23 ; 8.88 ] GeparNuevo, 2019, IMpassion-031 (all population), 2020 2 0% 505 low not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-31 23:51 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 305
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563,746,745,856,634,861,416,864,769,980,369,743